Rein Therapeutics to Present LTI-03 Research at ERS 2026 Congress
News provided byRein Therapeutics Inc · 1 min read
AUSTIN, Texas, Sept. 04, 2026 /CourierPR/ -- Rein Therapeutics, a biopharmaceutical company developing innovative treatments for rare lung diseases, will present groundbreaking research at the upcoming European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, from September 5-9, 2026.
The poster presentation, titled "Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study," will be showcased in the "Immunological mechanisms in pulmonary fibrosis" session on Tuesday, September 8, 2026, from 12:30 to 2:00 p.m. CEST. Dr. Philip Molyneaux, a professor of interstitial lung disease at Imperial College London and the Asthma+Lung UK Chair of Respiratory Research at the Royal Brompton Hospital, will be the presenter.
The poster will feature data from a study published in Nature Communications, highlighting the potential of LTI-03, a first-in-class inhaled peptide therapy. Derived from Caveolin-1 biology, LTI-03 is designed to inhibit lung scarring while preserving critical alveolar progenitor cells essential for tissue repair and regeneration.
LTI-03 is also the subject of Rein Therapeutics' RENEW Phase 2 trial, a randomized, placebo-controlled study enrolling approximately 120 patients in the U.S., U.K., Australia, Poland, and Germany. The trial is evaluating the safety and efficacy of LTI-03 in treating idiopathic pulmonary fibrosis. Key safety endpoints include the incidence of treatment-emergent adverse events through Week 24, with the primary efficacy measure being the change from baseline in forced vital capacity (FVC).
Rein Therapeutics is dedicated to addressing significant unmet medical needs in orphan pulmonary and fibrosis indications. LTI-03, the company's lead product, has received Orphan Drug and Fast Track designations in the U.S.
This presentation at the ERS 2026 Congress underscores Rein Therapeutics' commitment to advancing novel therapies for pulmonary diseases, potentially offering new hope to patients suffering from idiopathic pulmonary fibrosis.